Cost of Screening Outside of IPP Chlamydia Screening Guidelines

Slides:



Advertisements
Similar presentations
Chlamydia Screening Rates among Pregnancy Test Only Visits in Region I, Andee Krasner, MPH Region I IPP Infrastructure.
Advertisements

WI State Report RVIPP, Indianapolis, IN June 9-10, 2010.
State Report Region V IPP Advisory Committee Meeting June 9-10, 2010.
Assessment of Chlamydia Rescreening Practices Kelly Opdyke, MPH Region II IPP Advisory Committee Mtg May 16-17, 2007 Cicatelli Associates Inc.
Impact of a Targeted Provider Intervention to Improve Chlamydia Screening Practices in a Large California Family Planning Program Joan M. Chow 1, MPH,
Kat Smithson Policy and Campaigns Manager, NAT HIV prevention in England’s high prevalence local authorities: 2013/ /15 February 2015.
Revision of Region II IPP Screening Criteria May 16, 2007 Region II IPP Advisory Committee Meeting Cicatelli Associates Inc. New York City.
Repeat Chlamydial Infections in Region III Family Planning Clinics: Implications for Screening Programs Pamela G. Nathanson, Family Planning Council, Inc.
State of the Region Overview of APR Data for the Western Region Western Regional Resource Center APR Clinic 2010 November 1-3, 2010 San Francisco, California.
Region I Advisory Board Meeting Wells Beach, ME June 9, 2008 Use and Verification of STD Nucleic Acid Amplification Tests for non-FDA Cleared Clinical.
Noreen Clark, PhD Molly Gong, MD Melissa Valerio, MPH Sijian Wang, BS Xihong Lin, PhD William Bria, MD Timothy Johnson, MD University of Michigan School.
Evaluation of Gonorrhea Screening in Family Planning Settings: California 2000 CK Kent, M Brammeier, G Bolan, N Casas, M Funabiku, P Blackburn Region IX.
Appropriate CT/GC Screening & Factors to Consider Becky McCoy MSN, RN, CEN STD Nurse Consultant.
Analysis of Chlamydia Re-testing Rates Massachusetts Family Planning Update.
Reaching Out to Providers Summary of Region II IPP Tools.
Insert client logo Equal Pay findings QMUL November 2011.
RTI International is a trade name of Research Triangle Institute Untreated chlamydial infection among adolescents and young adults in Baltimore,
Re-Screening of CT Positive Clients in Region X IPP, Goldenkranz S., 1 Fine D. 1 1 Center for Health Training 2010 CDC STD Prevention Meeting,
Region I IPP Infrastructure Updates Advisory Board Meeting November 12, 2009 Boston, MA.
Region I IPP Clinic Staff and Provider Assessment Kim Watson, Jennifer Kawatu.
Division of HIV/AIDS Prevention CDC-RFA-PS
US Virgin Islands IPP: Use of Limited Resources Taetia Phillips-Dorsett, MS Territorial Director, USVI DOH STD/HIV/TB Program Region II IPP Advisory Meeting.
GC Outbreak in Philadelphia Greta Anschuetz, MPH Philadelphia Department of Public Health
Region I IPP Infrastructure Updates Advisory Board Meeting June 15, 2010 Boston, MA.
Collecting Site Positivity Data in Region I Andee Krasner, MPH Region I IPP Advisory Board Meeting.
Pilot Study: Re-screening Adolescent and Young Adult Women for Chlamydia Infection Alison Muse NYSDOH Bureau of STD Control Region II IPP meeting November.
IPP Future’s Project Update June 6 and 7, 2011 Region I IPP Advisory Board Meeting.
Region II IPP Data & Infrastructure Performance Measures Kelly Opdyke, MPH Region II IPP Advisory Committee Mtg May 16-17, 2007 Cicatelli Associates Inc.
IPP Measures of Effectiveness Utilization of Data to Evaluate and Inform Project Activities December 12, 2007 Kelly Morrison Opdyke, MPH Region II Infertility.
Infrastructure Update Jennifer Kawatu Kim Watson Andee Krasner
Targeting Chlamydia Screening Resources Region II IPP Advisory Meeting May 31, 2006 Kelly Opdyke, MPH Cicatelli Associates Inc.
BASELINE ASSESSMENT OF CHLAMYDIA REINFECTION IN REGION VIII FAMILY PLANNING CLINICS FOR Hamby, Y, JSI Research & Training Institute Donovan,
Legal Services Advisory Committee (LSAC) Grant Applicant Workshop February 4, 2011.
Region I IPP Data Presentation Advisory Board Meeting June 2008 Wells, ME.
Region II Infertility Prevention Project Advisory Committee May 16-17, 2007 New York, New York Steven J. Shapiro Infertility Prevention Project Coordinator.
IPP Infrastructure Measures of Effectiveness: Preliminary Data and Next Steps Kelly Morrison Opdyke, MPH Region II Infertility Prevention Project Cicatelli.
Region I IPP Advisory Board Meeting June 14 and 15, 2010 Wells, ME Chlamydia Testing during Pregnancy Test Only (PTO) Visits.
CONCLUSIONS New Jersey’s Emergency Department HIV testing sites report higher seroprevalence than non-ED testing sites. Since University Hospital began.
BASHH Conference, Oxford 2016
QUALITY OF CARE TRENDS FOR CALIFORNIA CHILDREN
THE COLORADO MODEL PROVIDER’S AT-RISK.
Universal Screening to Assess Chlamydia Prevalence and Risk Among Older Women Attending Family Planning Clinics in Wisconsin Roberta (Bobbie) McDonald.
Workshop on tracking of nutrition-relevant budget allocations Bangkok, April Conclusions and recommendations.
Class Notes November 9 & 10 © EMC Publishing, LLC.
Treasurer Financial Committee Report CTS Spring Planning Meeting San Marcos January 24, 2015 Don Drumtra Good morning.
Martin Goldberg1, Daniel R. Newman2, TA Peterman2,
HIV Diagnosis and the Cascade of Care in Ontario
2009 Market Rate Study Overview and Update.
Salary Planner Self Service Banner.
Steven J. Shapiro Infertility Prevention Project Coordinator
How the National Agreement Supports KP Strategy
Region I IPP Data Update Advisory Board Meeting
Prevalence of Rectal Chlamydia and Gonorrhea Before and After Implementation of Routine Rectal Screening Ellen T. Rudy Sexually Transmitted Disease Program.
Monitoring HPV vaccine impact in Connecticut
Treasurer Financial Committee Report CTS Spring Planning Meeting San Marcos January 16, 2015 Don Drumtra Good morning.
Infertility Prevention Project Coordinator CDC/CCID/NCHHSTP/DSTDP/PTB
Type of provider/facilities Private Sector Providers
Family Planning & STDP Brainstorming
Can Self-collected Vaginal Swabs Facilitate Testing for Repeat Chlamydia trachomatis Infections among STD Clinic Clients Good morning everyone! I am going.
Region I IPP Data Update Region I IPP Advisory Board Meeting
Influenza Vaccine Program Effectiveness in the United States
Region I IPP Data Update Region I IPP Advisory Board Meeting
2008 National STD Prevention Conference Chicago, Illinois
Rich Zimmerman Illinois Department of Public Health, Springfield IL
Region II IPP Performance Measure IPP CS1 and IPP CS2 Project Area Trend Report IPP CS1: Timely treatment of women with chlamydia at IPP Family Planning.
Region I IPP Data Update Region I IPP Advisory Board Meeting
Richard Steece, Ph.D., D(ABMM) National Infertility Prevention Project
California Budget & Propositions
Treatment Verification Rates for Chlamydia and Gonorrhea
Gonorrhea Screening: What Do the Data Tell Us?
Presentation transcript:

Cost of Screening Outside of IPP Chlamydia Screening Guidelines Andee Krasner, MPH Region I IPP Advisory Board Meeting June 6th, 2011

Background Cost of screening outside Chlamydia Screening Guidelines presented June 2010—data for 3 states, 2009-2010 Goal: develop tool for use by STD Directors to determine annual cost of screening outside guidelines ME piloted tool October 2010, copies distributed at November 2010 meeting Programs used tool for first time April 2011

Methods for Developing the Cost Analysis Tool Key informant interviews conducted in 2009 for original cost analysis Used to determine all steps of testing, end-to- end State IPP testing programs vary – the tool had to be flexible, but still collect same basic data across programs from ordering a test to reporting the test outcome for a client flexible to reflect differences in ordering test, collecting specimen, processing it and reporting it

Methods for Collecting Data Some programs have data from their budgets; others estimate. Asked states to indicate how much of data was estimated. How reliable are the data? More than half of data were estimated

2010: Percent of CT Tests Done Outside Guidelines Outside guidelines: 25-26 or older; no risk factors and no clinical signs of infection 30,722 tests done in women 2,214 outside guidelines Region I Average: 6% outside guidelines (Range: 1-19%) Data from Region I Prevalence Monitoring Data System Average (6%)

Positivity Rate of Tests Outside Guidelines Average CT positivity rate of women screened outside guidelines, across six states? 2% (Range: 0-2.93%) Below recommended 3% rate to be cost effective 2.35% if not weighted equally across states.

Average Cost of CT Test Paid for by IPP Average cost of CT test done outside IPP screening guidelines: $11.29 No one uses IPP budget to pay for all costs Purchase Test Distribute Specimen collection units -Collect specimen and send to Lab -Communicate results to client Lab processes specimen and communicates results to clinic Data Management Create swirly diagram indicating test process; label with avg cost; remove and speak last bullet point Average cost of CT test done outside IPP screening guidelines: $11.29 Costs may include: tests, distribution, specimen collection, client communication, courier, lab processing, data management No one uses IPP budget to pay for all costs

Real Costs of Testing Analysis includes only IPP test costs, not the full cost: Only one state paid for some medical services as part of IPP funding Cost for specimen collection and client communication was estimated to be far greater than what was paid to clinics to provide the service Not all lab processing costs accounted for

Impact on IPP Budget Average percent of budget spent on tests outside screening guidelines: 2% (range 1%- 17%) Impact of testing outside screening guidelines goes beyond IPP budget IPP Budget for Study Period $ 1,029,271.00 Number of tests done outside screening criteria 2214 Testing Kit Costs $ 13,545.67 Exam Costs $ 8,711.48 Laboratory Costs $ 2,740.71 TOTAL COST OF TESTS $ 24,997.86 ESTIMATED AVERAGE COST PER TEST DONE OUTSIDE SCREENING $ 11.29 COST OF TESTS OUTSIDE SCREENING CRITERIA   PERCENT OF BUDGET SPENT ON TESTS OUTSIDE SCREENING CRITERIA 2%

Conclusions CT positivity doesn’t support screening outside guidelines Money could be used to target populations with higher positivity True cost of screening outside CT screening guidelines goes beyond IPP paid tests, and impacts clinic and lab costs Variability in how states pay for testing makes estimating average cost of test difficult Data not reliable—more than half estimated

Questions?